University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Peter R. Carroll, M.D.

Co-director of Urologic Cancer

Dr. Peter Carroll, co-director of Urologic Cancer at the UCSF Helen Diller Family Comprehensive Cancer Center and chair of Urology at UCSF, is an expert in managing urologic cancers. His areas of interest include innovative methods of urinary tract reconstruction and the impact of cancer detection and treatment on quality of life.

Carroll has authored hundreds of publications, serves as associate editor of the Journal of Urology and plays a key role in other journals. He is principal or co-investigator of many peer-reviewed research grants. Carroll holds the Ken and Donna Derr-Chevron Distinguished Professorship. He graduated with honors from Georgetown University School of Medicine and came to UCSF for general surgery training and a urology residency. He completed a fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center before returning to UCSF.

Read a Q&A with Carroll.

Clinics

Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Peter R. Carroll

Education

Georgetown University 1979

Residencies

UCSF, Urology 1984

Fellowships

Memorial Sloan-Kettering Cancer Center

Selected Research and Publications

  1. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 7; 314(1):80-2.
  2. Hilmer SN, Seale JP, Carroll PR. A comparison of medical and pharmacy students' knowledge and skills of pharmacology and pharmacotherapy. Br J Clin Pharmacol. 2015 Jun; 79(6):1028-9.
  3. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015 Aug; 75(11):1206-15.
  4. Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May; 51(7):817-24.
  5. Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll PR, Cooperberg MR. Current Use of Imaging after Primary Treatment of Prostate Cancer. J Urol. 2015 Jul; 194(1):98-104.
  6. Schreuder LJ, Carroll P, Muwanguzi-Karugaba J, Kokoczka R, Brown AC, Parish T. Mycobacterium tuberculosis H37Rv has a single nucleotide polymorphism in PhoR which affects cell wall hydrophobicity and gene expression. Microbiology. 2015 Apr; 161(Pt 4):765-73.
  7. Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes. J Urol. 2015 Jul; 194(1):85-90.
  8. Bangma CH, Valdagni R, Carroll PR, van Poppel H, Klotz L, Hugosson J. Active Surveillance for Low-risk Prostate Cancer: Developments to Date. Eur Urol. 2015 Apr; 67(4):646-8.
  9. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10.
  10. Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, Carroll PR, Chan JM. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate. 2015 Jan; 75(1):60-9.
  11. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
  12. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11).
  13. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219.
  14. Klein EA, Cooperberg MR, Carroll PR. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol 2014;66:550-60. Eur Urol. 2014 Dec; 66(6):e117-8.
  15. Akaza H, Kim CS, Carroll P, Choi IY, Chung BH, Cooperberg MR, Hirao Y, Hinotsu S, Horie S, Lee JY, Namiki M, Ng CF, Onozawa M, Ozono S, Ueno S, Umbas R, Ye D, Zhu G. Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int. 2014; 2(2):50-69.
  16. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597.
  17. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014 Sep; 66(3):550-60.
  18. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51.
  19. Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014 May; 24(3):288-92.
  20. Carroll PR, Vickers AJ. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences? J Natl Compr Canc Netw. 2014 May; 12(5 Suppl):768-71.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.